---
document_datetime: 2023-09-21 19:24:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/raplixa-epar-all-authorised-presentations_en.pdf
document_name: raplixa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8393851
conversion_datetime: 2025-12-30 10:05:27.413549
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength           | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|--------------------|-----------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/14/985/001  | Raplixa           | 79 mg/g / 726 IU/g | Sealant powder        | Epilesional use           | vial (glass)          | 0.5 g                     | 1 vial      |
| EU/1/14/985/002  | Raplixa           | 79 mg/g / 726 IU/g | Sealant powder        | Epilesional use           | vial (glass)          | 1 g                       | 1 vial      |
| EU/1/14/985/003  | Raplixa           | 79 mg/g / 726 IU/g | Sealant powder        | Epilesional use           | vial (glass)          | 2 g                       | 1 vial      |

<!-- image -->